Literature DB >> 33454418

Assessment of Myocardial Fibrosis Using Two-Dimensional and Three-Dimensional Speckle Tracking Echocardiography in Dilated Cardiomyopathy With Advanced Heart Failure.

Jing Wang1, Yanting Zhang1, Li Zhang1, Fangyan Tian1, Bin Wang1, Yuji Xie1, Wei Sun1, Zhenxing Sun1, Yali Yang1, Qing Lv1, Nianguo Dong2, Yuman Li3, Mingxing Xie4.   

Abstract

BACKGROUND: This study aimed to depict strain parameters derived from 2-dimensional (2D)- and 3-dimensional (3D) speckle tracking echocardiography and to explore which may best reflect myocardial fibrosis (MF) in dilated cardiomyopathy with advanced heart failure by comparing with histologic fibrosis. METHODS AND
RESULTS: We analyzed 75 patients with dilated cardiomyopathy with advanced heart failure who underwent echocardiographic examination before heart transplantation. Strain parameters derived from 2D- and 3D speckle tracking echocardiography were as follows: left ventricular global longitudinal strain (GLS), global circumferential strain (GCS), global radial strain (GRS) and tangential strain (TS). The degree of MF was quantified using Masson's staining in left ventricular myocardial samples obtained from all patients. Seventy-five patients were divided into 3 groups according to the tertiles of histologic MF (mild, moderate, and severe MF groups). Patients with severe MF had lower 3DGLS, 3DGRS, 3DTS, and 2DGLS than those with mild and moderate MF. MF strongly correlated with 3DGLS (r = 0.72, P < .001), weakly with 3DGRS (r = -0.39, P = .001), 3DGCS (r = 0.30, P = .009), 3DTS (r = 0.47, P < .001), and 2DGLS (r = 0.44, P < .001), but did not correlate with 2DGCS and 2DGRS. Receiver operating characteristic analysis revealed that the area under the curve of 3DGLS for detecting severe MF was significantly larger than that of other strain parameters (0.86 vs 0.59-0.70, P < .05 for all). The multivariate linear regression models using 3DGLS (R2 = 0.76; Akaike information criterion = 331) was found to be a more accurate indicator to predict MF than that with 3DTS (R2 = 0.65, Akaike information criterion = 354) and 2DGLS (R2 = 0.66, Akaike information criterion = 352).
CONCLUSIONS: Three-dimensional GLS may be an optimal surrogate marker for reflecting MF in patients with dilated cardiomyopathy with advanced heart failure.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dilated cardiomyopathy; Myocardial fibrosis; Speckle tracking echocardiography; three-dimensional

Year:  2021        PMID: 33454418     DOI: 10.1016/j.cardfail.2021.01.003

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  5 in total

1.  Cardiac fibrosis in oncologic therapies.

Authors:  René R Sevag Packard
Journal:  Curr Opin Physiol       Date:  2022-08-08

2.  Association Between 2D- and 3D-Speckle-Tracking Longitudinal Strain and Cardiovascular Magnetic Resonance Evidence of Diffuse Myocardial Fibrosis in Heart Transplant Recipients.

Authors:  Wei Sun; Xuehua Shen; Jing Wang; Shuangshuang Zhu; Yanting Zhang; Chun Wu; Yuji Xie; Yun Yang; Nianguo Dong; Guohua Wang; Yuman Li; Qing Lv; Bo Liang; Li Zhang; Mingxing Xie
Journal:  Front Cardiovasc Med       Date:  2021-11-30

Review 3.  Echocardiographic Advances in Dilated Cardiomyopathy.

Authors:  Andrea Faggiano; Carlo Avallone; Domitilla Gentile; Giovanni Provenzale; Filippo Toriello; Marco Merlo; Gianfranco Sinagra; Stefano Carugo
Journal:  J Clin Med       Date:  2021-11-25       Impact factor: 4.241

Review 4.  Strain Imaging for the Early Detection of Cardiac Remodeling and Dysfunction in Primary Aldosteronism.

Authors:  Yilin Chen; Tingyan Xu; Jianzhong Xu; Limin Zhu; Dian Wang; Yan Li; Jiguang Wang
Journal:  Diagnostics (Basel)       Date:  2022-02-20

5.  Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients.

Authors:  Chuanqiang Wang; Yiteng Qin; Xiaojun Zhang; Yang Yang; Xuan Wu; Jing Liu; Shuhui Qin; Ke Chen; Wenliang Xiao
Journal:  Dis Markers       Date:  2022-09-05       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.